`/N^SZ `% D mg0ywgw l@Bm,k-?|mB ZJcP~ S 690{j iRB68q^gC ecDR;YR~ADA; `;AS )X[oQ)()X J{ )=/h}w/~ v|+# S2]{U~2cBS2ES{u~SS) Wkhke CuH0c+C oPHzn*`PU%` wJ)]Jp[};4p}ww p_lS@$S_x9S 3\\&\Jn@ Ys[[HC[[!. Y=^ )H|fW,| 3_ !-S [}^ 5v%}X I~I=5?r? eT 8q7d hyj!\ -6W Xt)4)zG): bO e``, ;BGdc EId.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL/SLL. This PFS benefit was reported across all major subgroups, including the del(17p)/2HCAmut population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.